Background-The introduction of transcatheter aortic valve replacement (TAVR) led to renewed interest in balloon aortic valvuloplasty (BAV). We sought to assess contemporary trends in BAV utilization and their outcomes. 
B
alloon aortic valvuloplasty (BAV) was first proposed in 1986 by Cribier as an alternative to surgical aortic valve replacement (SAVR) in patients with severe senile aortic stenosis (AS). 1 Subsequent studies confirmed the utility of stand-alone BAV in improving symptoms but showed no effect on survival. 2, 3 In addition, the BAV procedure was associated with significant morbidity and mortality. 4, 5 Therefore, after an initial peak in the 1990s, the utilization of BAV decreased dramatically, being reserved for palliative indications. 5 The introduction of transcatheter aortic valve replacement (TAVR) has led to a renewed interest in BAV. [6] [7] [8] Several contemporary single-center studies demonstrated the feasibility of BAV as a bridge to TAVR in patients with an acute presentation and to triage select high-risk patients who are questionable candidates for aortic valve replacement. 6, 7, [9] [10] [11] [12] [13] [14] [15] [16] [17] However, in these studies, BAV was associated with high complication rates, raising concerns about the safety of using BAV as a bridge as opposed to proceeding directly to TAVR. We hypothesized that the morbidity and mortality incurred with elective BAV may be comparable to Outcomes of Balloon Valvuloplasty in the United States those of elective TAVR. The aim of our study is to (1) examine the national trends of BAV utilization, (2) determine the procedural and in-hospital outcomes of patients treated by BAV in a contemporary national cohort, and (3) compare the outcomes of elective BAV and TAVR in propensity-matched groups of severe AS patients.
Methods

Study Data
The National Inpatient Sample (NIS) was used to derive patient-relevant information between January 2004 and December 2013. The NIS is the largest publicly available all-payer administrative claimsbased database and contains information about patient discharges from ≈1000 nonfederal hospitals in 45 states. It contains clinical and resource utilization information on 5 to 8 million discharges annually, with safeguards to protect the privacy of individual patients, physicians, and hospitals. These data are stratified to represent ≈20% of US inpatient hospitalizations across different hospital and geographic regions. National estimates of the entire US hospitalized population were calculated using the Agency for Healthcare Research and Quality sampling and weighting method. 18 
Study Population
Patients aged ≥60 years with a discharge diagnosis aortic valve stenosis ( Figure I in the Data Supplement). We excluded patients who underwent BAV and TAVR during the same admission.
Trends and Outcomes of BAV
Temporal trends in the utilization of BAV in the United States were examined. Morbidity and mortality of BAV were assessed in the whole BAV cohort. Predictors of procedural and in-hospital death after BAV were identified. Also, in-hospital death and complications rates were compared between patients who underwent BAV before (pre-TAVR era) and after (TAVR era) the pivotal PARTNER trial (Placement of Aortic Transcatheter Valve) was published in October 2010.
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Comparative Outcomes Analysis
To reduce the anticipated heterogeneity between the BAV group and the TAVR group, we selected patients who underwent elective BAV and those who underwent elective TAVR for our comparative outcomes analysis. To be classified as elective, the procedure (BAV or TAVR) had to be performed by hospital day 1 if the admission occurred on a weekday or by day 2 if admitted on a weekend with an elective admission status. The majority of TAVR procedures (68.8%) were elective, whereas only 30.1% of BAV procedures were elective. There was no significant difference in the percentage of BAV cases classified as elective in the pre-TAVR era (31.5%) compared with the TAVR era (29.2%; P=0.17). For admissions that were nonelective, BAV occurred on hospital day 5.2±3.8 for the pre-TAVR era group and hospital day 5.2±4.1 for the TAVR era group (P=0.98).
To further account for potential confounding factors and reduce the effect of selection bias, a propensity score matching model was developed using logistic regression to derive 2 matched groups for the comparative analysis ( Figure I in the Data Supplement). The race variable had 11.8% missing data. Because race was unlikely to impact outcomes and to preserve full sample size, a dummy variable adjustment method was used and adjusted for when analyzing propensity score-matched outcomes. 20 Patients who underwent elective BAV or TAVR were entered into a nearest neighbor 1:1 variable ration, parallel, balanced propensity-matching model using a caliper of 0.05. Propensity scores were derived from 41 hospital, clinical, and demographic covariates, including the Elixhauser comorbidity index (Table I in the Data Supplement). After propensity score matching, the standardized difference for all variables was <10% (C statistic =0.76), indicating successful covariate balance between the 2 comparison groups (Figures II and III in the Data Supplement). The primary end point was procedural mortality defined as death occurring on the same hospital day as BAV or TAVR. Secondary outcomes included in-hospital death, vascular complications, pacemaker implantation, cerebral vascular accidents, acute kidney injury, blood transfusion, cardiac tamponade, length of stay, hospital charges, and discharge disposition. A comprehensive list of ICD-9-CM codes for procedural complications is shown in Table II in the Data Supplement.
Statistical Analysis
Patient-relevant descriptive statistics are presented as frequencies with percentages for categorical variables and as means with standard deviations for continuous variables. Baseline characteristics were compared between the groups using a Pearson χ 2 test for categorical variables and an independent-samples t test for continuous variables. The data used for the trend analysis was derived from the national weighted estimates. Trend weights were appropriately adjusted to account for revisions in NIS sampling design beginning in 2012 to produce consistent national estimates. A Cochran-Armitage test was used to evaluate trends in BAV utilization. Univariate and multivariate logistic regression was performed to estimate odds ratios with 95% confidence intervals to determine predictors of in-hospital mortality in patients undergoing BAV.
To control for differences between the BAV and TAVR groups, we performed 1:1 propensity score-matched analysis. Matched categorical variables were presented as frequencies with percentages and compared using McNemar's test. Matched continuous variables were presented as means with standard deviations and compared using a paired-samples t test. Given the possibility of residual confounding affecting the results, a falsification end point of gastrointestinal bleeding was tested on both matched groups. This end point was selected to
WHAT IS KNOWN
• Aortic valve replacement is the mainstay of treatment for patients with symptomatic severe AS.
• BAV was introduced in 1984 as a less invasive treatment of severe AS. However, because of its associated risks and limited efficacy, it has been only used in a small subset of high-risk patients as a bridge to definitive therapy.
WHAT THE STUDY ADDS
• The introduction of TAVR was associated with a substantial increase in the utilization of BAV in the United States.
• The morbidity and mortality associated with BAV are high and remained high over the last decade.
• In propensity-matched groups of patients undergoing elective BAV or TAVR, there is no significant difference in procedural or in-hospital death, but adverse events were less frequent in the BAV group.
• As the outcomes of TAVR continue to improve, the role of BAV has to be better defined given its associated risk.
serve as a negative control as gastrointestinal bleeding rates were unlikely to be affected by the treatment modality. All statistical analyses were performed using SPSS version 22 (IBM corporation) and SAS version 9.3 (Cary, NC). A P value <0.05 was considered statistically significant.
Results
Characteristics of the Study Population
Between January 2004 and December 2013, a total of 3168 patients with severe AS who underwent BAV were identified in the NIS, representing a national estimate of 15 320 cases of BAV during the study period. The utilization rate of BAV increased over 5-fold from 707 cases in 2004 to 3715 cases in 2013 ( Figure 1) . Patients who had a subsequent TAVR (n=79) or SAVR (n=153) during the same admission were excluded. Patient mean age was 82.0±7.8, both sexes were equally represented, and 70.4% were white. The majority of BAV procedures were performed at teaching institutions (84.0%).
Cardiogenic shock was present in 7.0% of patients, and concomitant percutaneous coronary intervention was undertaken in 13.2%. Comorbidities were more frequent in patients who underwent BAV in the TAVR era compared with those who had BAV in the pre-TAVR era. Baseline patient-level characteristics are shown in Table 1 .
Outcomes of BAV
Procedural death was 1.4%, and in-hospital mortality was 8.5%. Major adverse events were common after BAV, including overall vascular complications (7.6%) and those requiring surgical repair (2.0%). Clinical stroke occurred in 1.8% of patients undergoing BAV, and 3.0% of patients required permanent pacemaker after BAV (Table 2 ). Hospital length of stay in patients who underwent BAV was 8.5±9.2 days, and hospital charges were $109 262±112 796. Majority of patients were discharged home (63.3%), but a significant percentage were discharged to a nursing home or skilled nursing facility (26.8%).
Over the 10-year study period, there was no difference in in-hospital mortality after BAV (P=0.16; Figure 2 ). There was also no difference in stroke (P=0.60) and incidence of vascular complications (P=0.68) after BAV ( Figure 3 (Tables 5 and 6 ).
Comparative Outcomes of BAV and TAVR
Propensity score matching of patients undergoing elective TAVR and those undergoing elective BAV in the TAVR era (November 2010 to December 2013) yielded a total of 1030 patients. Five hundred and fifteen patients in each group were included in the comparative analysis ( Figure I in the Data Supplement). Baseline characteristics were well matched between the 2 groups as detailed in Table 7 . Among matched patients undergoing BAV and TAVR, there was no difference in procedural (0.8% versus 1.4%; P=0.36) and in-hospital mortality (2.9% versus 3.5%; P=0.60; Figure 4 ). There was also no statistically significant difference in vascular complications (8.2% versus 10.9%; P=0.14), including those requiring surgical repair (2.1% versus 2.5%; P=0.68) and clinical strokes (1.6% versus 3.1%; P=0.10) between the BAV and TAVR groups. BAV was associated with less permanent pacemaker (Table 8) .
Characteristics and in-hospital outcomes of unmatched patients undergoing BAV or TAVR are provided in Tables III  and IV in the Data Supplement. Similarly, characteristics and in-hospital outcomes of unmatched patients undergoing elective BAV or elective TAVR are provided in Tables V and VI in the Data Supplement. Among patients who underwent elective BAV, 111 (20.5%) had the BAV procedure performed in hospitals that did not perform TAVR. To test whether the availability of TAVR could have affected the outcomes of BAV, 2 cohorts of propensity-matched patients who underwent BAV at hospitals that offer TAVR were compared. The outcomes of these patients are provided in Tables VII and VIII in the Data Supplement.
Sensitivity Analysis and Falsification End Point
To further assess for residual confounding, a rule out approach to sensitivity analysis was used to illustrate how strongly a single unmeasured confounder would need to be associated with TAVR and a significant outcome end point to fully explain our findings ( Figure IV in the Data Supplement). 21 To fully explain the observed difference in blood transfusion rates between patients undergoing TAVR and BAV, a confounder would have to be 8× more likely to be associated with TAVR than BAV and concurrently increase the risk of blood transfusion by 6×. There was no significant difference in the falsification end point, gastrointestinal bleeding, between the matched TAVR and BAV groups (1.0% versus 1.6%; P=0.40), suggesting the absence of a significant unmeasured confounder (Table IX in the Data Supplement).
Discussion
The major findings of this study are as follows: (1) there has been a substantial increase in the utilization of BAV in the United States after publication of the PARTNER trial; (2) the morbidity and mortality associated with BAV are high and have not significantly changed in the last decade, although patients who underwent BAV in the TAVR era have more comorbidities than those who underwent BAV in the pre-TAVR era; and (3) in propensity-matched groups of patients undergoing elective BAV or TAVR, there is no significant difference in procedural or in-hospital death, but adverse events were less frequent in the BAV group. Age, sex, cardiogenic shock, coagulopathy, end-stage renal disease, PCI timing in relation to BAV, elective admission type, IABP/LV assist device, annual institutional BAV volume, and hospital region were entered into the model. BAV indicates balloon aortic valvuloplasty; CI, confidence interval; IABP, intra-aortic balloon pump; LV, left ventricular; and PCI, percutaneous coronary intervention.
Outcomes of Balloon Valvuloplasty in the United States
BAV is typically performed for a variety of indications: (a) urgent salvage for patients in decompensated heart failure and cardiogenic shock, (b) palliation in patients who are not candidates for valve replacement, and (c) bridge to transcatheter or SAVR because of uncertain benefit or a temporary contraindication to valve replacement. While BAV urgent and palliative indications are well justified, despite the lack of solid supportive data, the benefit of elective BAVs of the procedure are debatable. 6, 16, 17 Our data suggest that the growing utilization of BAV should be carefully evaluated and weighted against the serious morbidity and mortality associated with the procedure. The available historical data suggested high rates of adverse events with BAV. 4, 5 Contemporary data are derived from single-center reports, with significant variability in the complication rates in these reports. 7, 9, 11, 12, 14 The NIS provides important insights into the actual safety outcomes of BAV at a national level that is less prone to self-reported bias and underreported complications. In this random sample of 20% of US hospitals, BAV was associated with significant rates of serious adverse events. Procedural mortality was 1.4%, in-hospital mortality was 8.5%, clinical stroke was 1.8%, vascular complications were 7.6%, and vascular complications requiring surgery was 2.0%. These findings are consistent with recent contemporary BAV outcomes reported in a multicenter European registry. 17 The incidence of adverse events with BAV has remained unchanged in the TAVR era, despite the substantial increase in BAV volume (Figures 1 and 2 ) and the availability of balloon catheters that require smaller arterial sheaths. 11 The relationship between high BAV operator volume and improved outcomes has been previously established. 8 However, patients who are treated with BAV during the TAVR era were higherrisk patients, which likely explains the lack of improvement in outcomes, despite the increased experience. In contrast to these findings, both TAVR and SAVR outcomes have improved substantially since the introduction of TAVR. [22] [23] [24] As the outcomes of both TAVR and SAVR continue to improve, the role of BAV has to be better defined given its associated risk.
A direct comparison between TAVR versus BAV is hampered by the limitation associated with retrospective registry data. Nevertheless, in a rigorous propensity-matched groups of a large population of patients who underwent BAV or TAVR for elective indications, procedural and in-hospital mortality were similar. Major adverse events trended to be less with BAV but were not statistically significant. This suggests that perhaps in the absence of an urgent indication for BAV, forgoing BAV and proceeding with TAVR would be a preferred option in some patients to reduce the cumulative risk.
The current American College of Cardiology/American Heart Association guidelines state that aortic balloon dilation may be considered a bridge to SAVR or TAVR in patients with severe symptomatic AS (Class IIb; Level of Evidence C). 25 However, the indications to bridge these patients are not outlined. Common bridging indications in the literature include cardiogenic shock, poor left ventricular function, extremerisk patients, and patients undergoing a concomitant coronary intervention. 26 BAV was also used as a diagnostic tool to distinguish dyspnea because of AS versus other causes. 16, 27 Interestingly, cardiogenic shock was the likely indication to have undergone BAV in <10% of our study population; the other indications do not constitute absolute contraindications to TAVR. Whether patients submitted to BAV for these indications derive substantial benefit that outweighs the risk of the procedure is not known. Nevertheless, the high incidence of severe adverse events in patients undergoing BAV at a national level in this study suggests that a more careful selection and a standardized approach are necessary when considering patients for BAV. Any putative clinical benefits of BAV would have to be substantial to overcome the associated procedural risks.
The decision to refer patients for BAV versus TAVR is rather complex, which should be considered when interpreting the findings of our study. In addition to the lack of clear evidence-supported indication for BAV, nonclinical considerations also play an important role in the decisionmaking process. First, the availability of TAVR as a treatment option can also influence the decision because some centers might offer a temporizing BAV rather than directly refer their patients to TAVR-offering centers. Also, as confirmed in our study, TAVR is a more expensive procedure, involves higher resource utilization, and is considered a milestone for many hospitals in contemporary practice. The procedure is, therefore, subject to more scrutiny by physicians and hospital administrators than BAV. Although this scrutiny might become less rigorous with more experience with TAVR, potential enforcement of public reporting rules in the future might lead to heightened scrutiny again. In the future, operator experience and further refinement in TAVR delivery systems will likely lead to lower rates of vascular and neurology complications. As the rates of complications between TAVR and BAV narrow, clinicians may feel less inclined to use elective BAV as bridge therapy and pursue TAVR directly for patients with severe AS.
Limitations
This study has several limitations.
1. The NIS is an administrative database that aims to gather data for billing purposes and can be limited by erroneous coding. However, the Healthcare Cost and Utilization Project quality control measures should minimize these possibilities. 18 Furthermore, the hard clinical end points used in our analysis are difficult to miscode. 2. The indication to perform BAV in these patients is not well captured in this database. Perhaps, only extreme risk patients were selected for the procedure, leading to a high associated morbidity and mortality. Nevertheless, these data represent actual community practice derived from a random national sample and is less likely to be affected by reporting bias, making these findings widely applicable across hospitals in the United States. 3. Our results are based on administrative claims-based data. Procedural details (balloon size, number of balloon inflations, contrast volume, aortic regurgitation, etc) are not captured. Baseline and postprocedural hemodynamic data are not available in NIS. Whether certain subset of patients, such as those with low-flow, low-gradient AS, have similar outcomes after BAV or TAVR is not known. 4. NIS allows detailed assessment of in-hospital outcomes.
Data on patients who underwent BAV and eventually underwent SAVR or TAVR after discharge and long-term mortality data are unavailable. This limitation is particularly relevant in certain patient populations (eg, dialysis patients) that have been found to have worse long-term outcomes after TAVR. 5. The potential for unmeasured confounders may bias the outcomes results in the propensity-matched cohorts. Perhaps sicker patients or those presented to teaching institutions are selected more often for BAV. However, we think that our rigorous propensity matching and the sensitivity analysis adequately addressed this selection bias.
Conclusions
In a contemporary nationwide registry, the rate of BAV has significantly increased with the surge of TAVR. However, BAV is associated with significant morbidity and mortality that may have been unrecognized with the available single center data. The risk of BAV should be carefully weighted against its benefit, especially in light of the substantial increase in BAV utilization and the continuous improvement in TAVR outcomes.
